Body Composition and Leptin/Ghrelin Levels during Lenvatinib for Thyroid Cancer.

ABSTRACT: Weight loss is one of the most frequent adverse events during treatment with multikinase inhibitors, but scanty data are available on its extent and characteristics. This is the first assessment of the body composition by bioelectrical impedance analysis and of circulating leptin and ghrelin levels, in patients with advanced thyroid cancer before and at regular intervals during treatment with the tyrosine kinase inhibitor lenvatinib. Body mass index (BMI) decreased in all patients, with an average ∆ reduction of -6.4, -9.8, and -15.3% at 3, 6, and 12 months of treatment, respectively. Interestingly, in most patients, after the first year of treatment, BMI remained stable. In all patients, fat mass (FM) reduced more than fat-free mass, the highest decrement being of -60 and -16%, respective

SUBMITTER: De Leo S 

PROVIDER: S-EPMC7024882 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature